Many more targeted therapies are now available for people with AML, in both the newly diagnosed and relapsed/refractory settings. Learn about the genetic and protein targets, and their associated therapeutics, in this review.
The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.
Tissue biopsy is the gold standard for diagnosis in T-cell lymphoma, but is not always feasible. Could liquid biopsy be used instead, and not just for diagnosis but also for monitoring treatment response?
A patient receiving arsenic trioxide for acute promyelocytic leukemia developed drug-induced acute pericarditis that was successfully treated with colchicine.
When newborns present with clinical signs such as rash, distal extremity desquamation, and cervical lymph adenitis, and simultaneous increases in peripheral blood leukocyte count and platelets, clinicians should be highly alert to KD even without fever.
A cohort study suggests that the prophylactic use of tixagevimab–cilgavimab may reduce the incidence and severity of COVID-19 in patients with hematologic cancers.
A case series of three patients suggests that obinutuzumab-induced acute thrombocytopenia is a frequent, possibly non-relapsing, and unique adverse event that deserves more attention than it currently receives.
Richter’s transformation is a rare complication of chronic lymphocytic leukemia that is associated with poor outcomes. The evolving landscape of its treatment is discussed in this review.
Following an orthopedic trauma and DVT, a patient received an inferior vena cava filter intended to prevent pulmonary embolism. However obstructive shock developed secondary to extensive inferior vena cava thrombosis caused by inadequate anticoagulant therapy.
Time-limited treatment is one of the cornerstones of modern CLL management. This review provides an overview of the current therapies as well as an outlook on studies and datasets needed to optimize the use of these strategies.
This review presents recent data on endocrinopathies in patients with beta thalassemia, including their prevalence, proposed pathogenetic mechanisms, risk factors, diagnosis, and recommended treatment options.
Coronary artery fistulas are rare coronary anomalies that most often occur as congenital malformations in children. Cardiologists should understand the classifications of CAFs in children, as well as the short and long-term outcomes of CAF closure.
A wide range of complementary and integrative approaches are being studied in lymphoma and may prove beneficial for patients. But better patient–practitioner communication and systematic evaluation of potential safety issues are crucial.
The latest findings on cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia and recommendations to prevent and manage them are outlined.
Although cauda equina syndrome in the context of secondary CNS lymphoma is a rare occurrence, it should be considered in at-risk patients, especially those presenting with abnormal neurological findings.
The development of several FLT3 inhibitors has been a step forward in the treatment of FLT3-mutated acute myeloid leukemia, but challenges and questions remain.
No benefit of aspirin was found in patients on long-term antithrombotic therapy following left assist ventricular device implantation for heart failure.
